Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Total Investments?

  Alexion Pharmaceuticals Inc ( ALXN ) |
2006 - 2021 (16 years)

Total Investments is 
$205.2M (1Y +232% )

ALXN Stock Price & Total Investments

Total Investments for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Total Investments

chevron_right 2021 $68.9M -0.6x
( -5.5% / year avg)
chevron_left 2006 $169.0M
vertical_align_top Peak $169.0M -
vertical_align_bottom Bottom 0.0
arrow_drop_up # Up Years 3 3 of 16
years up.
arrow_drop_down # Down Years 1
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 2006 , or -75.0x faster than it's total investments over the same period.
  • If ALXN shrinks it's stock at the same rate as it's total investments (-5.5%/year) , it's stock price will shrink +56.8% and hit $61.75 over the next 10 years.
  • ALXN's stock price has gone up 1 of the 3 years (+33%) it's total investments were also up.
  • ALXN Historical Total Investments Table
    in $ million
    Year Total Investments YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $68 21.1% $108.72 -9.3%
    4/1/2020 $56 - $119.9 5.5%
    4/1/2019 $0 - $113.68 -2.1%
    4/1/2018 $0 - $116.13 18.5%
    4/1/2017 $0 - $98.03 -30.4%
    4/1/2016 $0 - $140.8 -21.9%
    4/1/2015 $0 - $180.37 2.0%
    4/1/2014 $0 - $176.8 91.9%
    4/1/2013 $0 - $92.14 -0.8%
    4/1/2012 $0 - $92.86 88.2%
    4/1/2011 $0 - $49.34 81.5%
    4/1/2010 $0 - $27.18 44.4%
    4/1/2009 $0 - $18.83 27.0%
    4/1/2008 $0 - $14.82 37.1%
    4/1/2007 $0 -100.0% $10.81 22.1%
    4/1/2006 $169 - $8.86 -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • An investment is an asset or item acquired with the goal of generating income or appreciation. Appreciation refers to an increase in the value of an asset over time. When an individual purchases a good as an investment, the intent is not to consume the good but rather to use it in the future to create wealth. An investment always concerns the outlay of some asset today—time, money, or effort—in hopes of a greater payoff in the future than what was originally put in.

    For more detailed definitions, please see Investopedia.